Ieq Capital LLC Buys New Stake in Merit Medical Systems, Inc. $MMSI

Ieq Capital LLC acquired a new stake in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 18,386 shares of the medical instruments supplier’s stock, valued at approximately $1,275,000.

Several other large investors have also recently made changes to their positions in the company. AQR Capital Management LLC raised its holdings in shares of Merit Medical Systems by 7.3% during the 1st quarter. AQR Capital Management LLC now owns 16,361 shares of the medical instruments supplier’s stock worth $1,730,000 after acquiring an additional 1,114 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Merit Medical Systems by 16.9% during the first quarter. Goldman Sachs Group Inc. now owns 719,313 shares of the medical instruments supplier’s stock valued at $76,039,000 after purchasing an additional 103,878 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Merit Medical Systems by 745.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 922 shares of the medical instruments supplier’s stock worth $86,000 after buying an additional 813 shares in the last quarter. First Trust Advisors LP increased its holdings in shares of Merit Medical Systems by 24.8% in the 2nd quarter. First Trust Advisors LP now owns 59,215 shares of the medical instruments supplier’s stock worth $5,535,000 after buying an additional 11,770 shares during the last quarter. Finally, Cerity Partners LLC raised its position in shares of Merit Medical Systems by 9.1% during the 2nd quarter. Cerity Partners LLC now owns 3,019 shares of the medical instruments supplier’s stock valued at $282,000 after buying an additional 251 shares in the last quarter. 99.66% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on MMSI. Canaccord Genuity Group upped their price objective on Merit Medical Systems from $85.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. boosted their target price on Merit Medical Systems from $77.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Piper Sandler boosted their price objective on Merit Medical Systems from $96.00 to $106.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Weiss Ratings upgraded Merit Medical Systems from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. Finally, Raymond James Financial reissued an “outperform” rating and set a $100.00 target price on shares of Merit Medical Systems in a research note on Friday, July 31st. Eight investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Merit Medical Systems presently has a consensus rating of “Moderate Buy” and an average price target of $100.00.

Merit Medical Systems Price Performance

Shares of MMSI stock opened at $90.54 on Thursday. Merit Medical Systems, Inc. has a twelve month low of $59.74 and a twelve month high of $94.75. The stock has a market capitalization of $5.41 billion, a price-to-earnings ratio of 37.41, a P/E/G ratio of 2.27 and a beta of 0.49. The stock has a fifty day simple moving average of $78.85 and a two-hundred day simple moving average of $72.74. The company has a current ratio of 4.20, a quick ratio of 2.79 and a debt-to-equity ratio of 0.44.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 EPS for the quarter, beating the consensus estimate of $0.96 by $0.23. Merit Medical Systems had a return on equity of 13.75% and a net margin of 9.22%.The firm had revenue of $418.84 million for the quarter, compared to analyst estimates of $405.25 million. During the same quarter last year, the firm posted $1.01 earnings per share. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. On average, analysts predict that Merit Medical Systems, Inc. will post 3.84 EPS for the current fiscal year.

Key Merit Medical Systems News

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Zacks Research raised several earnings forecasts. The firm increased its FY2026 EPS estimate to $3.73 from $3.57, FY2027 to $4.01 from $3.82, and FY2028 to $4.32 from $4.12. It also lifted estimates for Q2 2027, Q3 2027, Q1 2028, and Q2 2028. The revisions suggest improved confidence in Merit Medical’s longer-term earnings growth.
• Positive Sentiment: Longer-term earnings expectations are moving higher. The revised FY2027 and FY2028 forecasts exceed the current-year consensus estimate of roughly $3.81–$3.84 per share, reinforcing the outlook for continued earnings expansion.
• Neutral Sentiment: Short-interest data appears unusable. The report lists short interest at zero shares and describes the change as “NaN,” with a zero days-to-cover ratio. This does not provide a meaningful signal about short-selling pressure or potential short covering.
• Negative Sentiment: One near-term estimate was reduced. Zacks lowered its Q4 2026 EPS forecast slightly to $0.98 from $0.99. While the change is minor, it offsets some of the broader positive revisions and indicates limited near-term earnings impact.
• Negative Sentiment: Valuation leaves less room for disappointment. Merit Medical’s shares recently traded near their 52-week high, with a P/E ratio above 37 and a PEG ratio above 2. Stronger earnings expectations are supportive, but the premium valuation could weigh on the stock if results or guidance fall short.

Merit Medical Systems Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.